A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the ...

(Reuters) - Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene ...

A New York federal judge dismissed allegations on Monday that Bristol Myers Squibb purposely delayed Breyanzi’s approval to ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

The U.S. National Transportation Safety Board on Monday said more than 40 foreign operators of Boeing 737 airplanes may be ...

From financing the future of cleaner energy to influencing trades at the world's largest hedge fund, here's why these ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced the appointment of Braden Parker as Chief Commercial Officer, ...

Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...

Chicago-based venture-capital firm Arch Venture Partners has closed a new $3 billion fund to invest in early-stage ...

European auto stocks tumbled almost 4% on Monday after a warning from Stellantis, Volkswagen and Aston rekindled concerns ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

Dr Joseph Berger reviews findings showing how newer drugs like satralizumab, eculizumab, and inebilizumab outperformed older neuromyelitis optica spectrum disorder treatments.